{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:50:38Z","timestamp":1648795838637},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1007\/s11883-001-0053-4","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T19:22:37Z","timestamp":1179775357000},"page":"163-168","source":"Crossref","is-referenced-by-count":0,"title":["Low-molecular weight heparins in coronary artery disease"],"prefix":"10.1007","volume":"3","author":[{"given":"Dan","family":"Hunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"53_CR1","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","volume":"114","author":"J Hirsh","year":"1998","unstructured":"Hirsh J, Warkentin TE, Raschke R, and et al.: Heparin low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114:489S-510S.","journal-title":"Chest"},{"key":"53_CR2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"J Weitz","year":"1997","unstructured":"Weitz J: Low-molecular-weight heparins. N Engl J Med 1997, 337:688\u2013698.","journal-title":"N Engl J Med"},{"key":"53_CR3","doi-asserted-by":"crossref","first-page":"611S","DOI":"10.1378\/chest.114.5_Supplement.611S","volume":"114","author":"JA Cairns","year":"1998","unstructured":"Cairns JA, Theroux P, Lewis Jr HD, et al.: Antithrombotic agents in coronary artery disease. Chest 1998, 114:611S-633S.","journal-title":"Chest"},{"key":"53_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1345\/aph.16483","volume":"32","author":"SA Spinler","year":"1998","unstructured":"Spinler SA, Nawarskas JJ: Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998, 32:103\u2013110.","journal-title":"Ann Pharmacother"},{"key":"53_CR5","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.159.16.1849","volume":"159","author":"PJ Zed","year":"1999","unstructured":"Zed PJ, Tisdale JE, Borzak S: Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 1999, 159:1849\u20131857.","journal-title":"Arch Intern Med"},{"key":"53_CR6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","volume":"26","author":"EP Gurfinkel","year":"1995","unstructured":"Gurfinkel EP, Manos EJ, Mejail RI, et al.: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995, 26:313\u2013318.","journal-title":"J Am Coll Cardiol"},{"key":"53_CR7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","volume":"347","author":"L Wallentin","year":"1996","unstructured":"Wallentin L, Ohlsson J, Swahn E, et al.: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561\u2013568.","journal-title":"Lancet"},{"key":"53_CR8","doi-asserted-by":"crossref","first-page":"30E","DOI":"10.1016\/S0002-9149(97)00487-6","volume":"80","author":"W Klein","year":"1997","unstructured":"Klein W, Buchwald A, Hillis WS, et al.: Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol 1997, 80:30E-34E.","journal-title":"Am J Cardiol"},{"key":"53_CR9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447\u2013452.","journal-title":"N Engl J Med"},{"key":"53_CR10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.CIR.97.17.1702","volume":"97","author":"DB Mark","year":"1998","unstructured":"Mark DB, Cowper PA, Berkowitz SD, et al.: Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 1998, 97:1702\u20131707.","journal-title":"Circulation"},{"key":"53_CR11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-8703(00)90085-1","volume":"139","author":"BJ O\u2019Brien","year":"2000","unstructured":"O\u2019Brien BJ, Willan A, Blackhouse G, et al.: Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000, 139:423\u2013429.","journal-title":"Am Heart J"},{"key":"53_CR12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","volume":"100","author":"EM Antman","year":"1999","unstructured":"Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [comment]. Circulation 1999, 100:1593\u20131601.","journal-title":"Circulation"},{"key":"53_CR13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","volume":"354","author":"L Wallentin","year":"1999","unstructured":"Wallentin L, Swahn E, Kontny F, et al.: Long-term low-molecular mass heparin in unstable coronary-artery disease: FRISC II prospective multicentre study. Lancet 1999, 354:701\u2013707.","journal-title":"Lancet"},{"key":"53_CR14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","author":"Group TFISS","year":"1999","unstructured":"Group TFISS. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome) [comment]. Eur Heart J 1999, 20:1553\u20131562.","journal-title":"Eur Heart J"},{"key":"53_CR15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0003-4975(99)01366-1","volume":"68","author":"SC Clark","year":"2000","unstructured":"Clark SC, Vitale N, Zacharias J, Forty J: Effect of low molecular weight heparin (Fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 2000, 68:762\u2013765.","journal-title":"Ann Thorac Surg"},{"key":"53_CR16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0735-1097(00)00695-1","volume":"36","author":"G Montalescot","year":"2000","unstructured":"Montalescot G, Collet JP, Lison L, et al.: Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. Am J Cardiol 2000, 36:110\u2013114.","journal-title":"Am J Cardiol"},{"key":"53_CR17","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1053\/hj.1999.v138.a102299","volume":"138","author":"E Deutsch","year":"1999","unstructured":"Deutsch E: The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory. Am Heart J 1999, 138:S577\u2013585.","journal-title":"Am Heart J"},{"key":"53_CR18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(99)00582-2","volume":"84","author":"MM Rabah","year":"1999","unstructured":"Rabah MM, Premmereur J, Graham M, et al.: Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999, 84:1391\u20131395.","journal-title":"Am J Cardiol"},{"key":"53_CR19","first-page":"3C","volume":"12","author":"DA Tramuta","year":"2000","unstructured":"Tramuta DA, Kereiakes DJ, Dippel EJ, et al.: Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care? J Invas Cardiol 2000, 12:3C-6C.","journal-title":"J Invas Cardiol"},{"key":"53_CR20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/01.CIR.94.7.1553","volume":"94","author":"JA Cairns","year":"1996","unstructured":"Cairns JA, Gill J, Morton B, et al.: Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. Circulation 1996, 94:1553\u20131560.","journal-title":"Circulation"},{"key":"53_CR21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/01.CIR.90.2.908","volume":"90","author":"DP Faxon","year":"1994","unstructured":"Faxon DP, Spiro TE, Minor S, et al.: Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial. Circulation 1994, 90:908\u2013914.","journal-title":"Circulation"},{"key":"53_CR22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0735-1097(96)00343-9","volume":"28","author":"KR Karsch","year":"1996","unstructured":"Karsch KR, Preisack MB, Baildon R, et al.: Low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996, 28:1437\u20131443.","journal-title":"J Am Coll Cardiol"},{"key":"53_CR23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0002-9149(99)00141-1","volume":"83","author":"LW Gimple","year":"1999","unstructured":"Gimple LW, Herrmann HC, Winniford M, Mammen E: Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1999, 83:1524\u20131529.","journal-title":"Am J Cardiol"},{"key":"53_CR24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0002-8703(96)90454-8","volume":"132","author":"M Pan","year":"1996","unstructured":"Pan M, de Lezo JS, Velasco F, et al.: Reduction of thrombotic and hemorrhagic complications after stent implantation. Am Heart J 1996, 132:1119\u20131126.","journal-title":"Am Heart J"},{"key":"53_CR25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0002-9149(96)00152-X","volume":"77","author":"A Glick","year":"1996","unstructured":"Glick A, Kornowski R, Michowich Y, et al.: Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996, 77:1145\u20131148.","journal-title":"Am J Cardiol"},{"key":"53_CR26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0002-9149(00)01014-6","volume":"86","author":"M Cohen","year":"2000","unstructured":"Cohen M, Antman EM, Gurfinkel E, et al.: Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. Am J Cardiol 2000, 86:553\u2013556.","journal-title":"Am J Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-001-0053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-001-0053-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-001-0053-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:35:20Z","timestamp":1559417720000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-001-0053-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1007\/s11883-001-0053-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}